Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2013 Feb;15(2):518-26.
doi: 10.1093/ntr/nts173. Epub 2012 Sep 4.

Pharmacogenetic smoking cessation intervention in a health care setting: a pilot feasibility study

Jennifer B McClure  1 , Gary E Swan, Jackie St John, Randy Fauver, Harold S Javitz, Andrew W Bergen, Denise Nishita, Raymond Niaura, Marcus R Munafò, Sean P David
Affiliations
Randomized Controlled Trial

Pharmacogenetic smoking cessation intervention in a health care setting: a pilot feasibility study

Jennifer B McClure et al. Nicotine Tob Res. 2013 Feb.

Abstract

Introduction: There is increasing evidence that response to pharmacological treatment for nicotine dependence may be moderated by genetic polymorphisms. However, the feasibility, acceptability, and impact of genetically tailoring treatment in real-world clinical settings are unknown.

Methods: We conducted a multiphased, mixed-methods feasibility study with current smokers to develop and evaluate a patient-centered, theoretically grounded personalized medicine treatment protocol. The initial research phase included formative work to develop intervention materials. The second phase included a randomized pilot trial to evaluate the intervention. Trial participants (n = 36) were genotyped for ANKK1 rs1800497 and were randomized to receive genetic feedback (GF) plus standard behavioral counseling (BC) for smoking cessation or BC without GF. All participants received genetically tailored pharmacotherapy (nicotine patch or bupropion).

Results: The intervention was feasible to implement and was acceptable to participants based on satisfaction ratings and objective measures of participation. There was no evidence that the GF resulted in adverse psychological outcomes (e.g., depression, fatalism, reduced perceived control over quitting, differential motivation for quitting) based on quantitative or qualitative outcomes.

Conclusions: Study results suggest that it is feasible to offer treatment within a health care setting that includes genetically tailored pharmacotherapy and doing so had no apparent adverse psychological impacts. Further evaluation of pharmacogenetically tailored smoking cessation interventions appears warranted.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Recruitment flow for pilot trial.
See this image and copyright information in PMC

References

    1. Allison M. (2008). Is personalized medicine finally arriving? Nature Biotechnology 26 509–517doi:10.1038/nbt0508–509 - PubMed
    1. Altman R. B. (2011). Pharmacogenomics: “Noninferiority” is sufficient for initial implementation Clinical Pharmacology and Therapeutics 89 348–350doi:10.1038/clpt.2010.310 - PubMed
    1. Baars M. J., Henneman L., Ten Kate L. P. (2005). Deficiency of knowledge of genetics and genetic tests among general practitioners, gynecologists, and pediatricians: A global problem Genetics in Medicine 7 605–610doi:0.1097/01.gim.0000182895.28432.c7 - PubMed
    1. Breitling L. P., Müller H., Illig T., Rujescu D., Winterer G., Dahmen N, Brenner H., et al. (2011). Dopamine-related genes and spontaneous smoking cessation in ever-heavy smokers Pharmacogenomics 12 1099–1106 doi:10.2217/pgs.11.74 - PubMed
    1. Collier R. (2012). Genetic literacy poor in primary care CMAJ: Canadian Medical Association Journal 184 E467–E468doi:10.1503/cmaj.109-4188 - PMC - PubMed

Publication types